ZYLM (Central Asia Lumeichun Biotechnology) Change In Receivables: $-0.16 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Central Asia Lumeichun Biotechnology Change In Receivables?

Central Asia Lumeichun Biotechnology ZYLM Change In Receivables is $-0.16 Mil as of Jun. 2026.

Central Asia Lumeichun Biotechnology's change in receivables for the quarter that ended in Jun. 2026 was $-0.16 Mil. It means Central Asia Lumeichun Biotechnology's Accounts Receivable increased by $0.16 Mil from Mar. 2026 to Jun. 2026 .

Central Asia Lumeichun Biotechnology's change in receivables for the fiscal year that ended in Dec. 2025 was $-0.34 Mil. It means Central Asia Lumeichun Biotechnology's Accounts Receivable increased by $0.34 Mil from Dec. 2024 to Dec. 2025 .

Central Asia Lumeichun Biotechnology's Accounts Receivable for the quarter that ended in Jun. 2026 was $0.62 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Central Asia Lumeichun Biotechnology's Days Sales Outstanding for the three months ended in Jun. 2026 was 171.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Central Asia Lumeichun Biotechnology's liquidation value for the three months ended in Jun. 2026 was $-2.56 Mil.

Central Asia Lumeichun Biotechnology  (OTCPK:ZYLM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Central Asia Lumeichun Biotechnology's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.624605/0.332471*91
=171.43

2. In Ben Graham's calculation of liquidation value, Central Asia Lumeichun Biotechnology's accounts receivable are only considered to be worth 75% of book value:

Central Asia Lumeichun Biotechnology's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.003355-3.502611+0.75 * 0.624605+0.5 * 0.944255
=-2.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Asia Lumeichun Biotechnology Change In Receivables Related Terms

Central Asia Lumeichun Biotechnology Change In Receivables Historical Data

* Premium members only.

The historical data trend for Central Asia Lumeichun Biotechnology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Asia Lumeichun Biotechnology Change In Receivables Chart

Central Asia Lumeichun Biotechnology Annual Data
Trend Mar07 Mar08 Mar09 Mar10 Mar11 Mar14 Mar15 Aug23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.34

Central Asia Lumeichun Biotechnology Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun13 Jun15 Sep15 Dec15 Nov22 Feb23 May23 Aug23 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.40 -0.32 -0.16

Central Asia Lumeichun Biotechnology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.16 Mil mean?
Central Asia Lumeichun Biotechnology (ZYLM) has a Change In Receivables of $-0.16 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Central Asia Lumeichun Biotechnology and its competitors.
Is Central Asia Lumeichun Biotechnology's Change In Receivables too high?
Central Asia Lumeichun Biotechnology's current Change In Receivables is $-0.16 Mil.
How does Central Asia Lumeichun Biotechnology's Change In Receivables compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's Change In Receivables of $-0.16 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Consumer Packaged Goods company?
A good Change In Receivables depends on the Consumer Packaged Goods industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Central Asia Lumeichun Biotechnology and its competitors. Central Asia Lumeichun Biotechnology's current Change In Receivables is $-0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current Change In Receivables of $-0.16 Mil. The current Change In Receivables is $-0.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current Change In Receivables is $-0.16 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Asia Lumeichun Biotechnology Business Description

Address Longguan Avenue, Room 1401, Yunhua Building, Longhua District, Shenzhen, CHN
Central Asia Lumeichun Biotechnology Inc is an ecological agriculture company. It operates a sika deer breeding base in southern China.